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Background: Tiotropium is a long-acting inhaled anticholinergic developed for the treatment 
of chronic obstructive pulmonary disease (COPD) and has been available since 2002. We sought 
to update an evaluation of the safety of tiotropium in the HandiHaler® formulation as significant 
clinical trial data have become available over time.
Methods: Pooled analysis of adverse event reporting from phase III and IV tiotropium HandiHaler® 
clinical trials with the following characteristics was performed: randomized, double-blind, parallel 
group, placebo-controlled design, tiotropium 18 µg once-daily dosing, COPD indication, duration 
of at least four weeks. Incidence rates by treatment group, rate differences (tiotropium–placebo), 
and 95% confidence intervals were determined.
Results: Twenty-six trials were identified involving 17,014 patients. Mean age was 65 years, 
mean forced expiratory volume in one second was 1.16 L (41% predicted), 76% men. Total 
exposure to study drug was 11,958 patient-years (tiotropium) and 10,578 patient-years (placebo). 
Tiotropium was associated with a reduced risk (expressed as rate difference [95% confidence 
interval] per 100 patients-years at risk) for an adverse event (-17.5 [-22.9, -12.2]), serious 
adverse event (-1.41 [-2.81, -0.00]) and a fatal event (-0.63 [-1.14, -0.12]). A reduced risk 
was present for adverse events that were cardiac (-0.79 [-1.48, -0.09]), lower respiratory 
(-14.2 [-17.0, -11.5]) and for a composite endpoint of major adverse cardiovascular events 
(-0.45 [-0.85, -0.05]). Typical expected inhaled anticholinergic effects such as dry mouth, 
constipation, and urinary difficulties were observed in the safety database.
Conclusion: The safety data review does not indicate an increased risk for death or cardiovas-
cular morbidity during tiotropium treatment in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive disorder that is a major 
cause of morbidity, disability, and death. Analyses of administrative claims databases 
confirm the increased risk of death due to COPD relative to a healthy population.1 
Patients with advanced COPD will often die from progressive parenchymal destruction 
and/or structural narrowing of the small airways that leads to airflow limitation, 
hyperinflation, exacerbations and respiratory failure. Indeed, mortality has been 
shown to be related to the severity of disease using either a simple measure such as 
forced expiratory volume in one second (FEV1) or to other disease measures such as 
exercise tolerance and disease specific quality of life measurements.2–5 Furthermore, 
a reduced FEV1 appears to be a risk factor for cardiac disease and is also accompanied 
by multiple comorbidities.6 However, it may be difficult to separate the independence International Journal of COPD 2009:4 398
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of COPD as a risk factor for nonrespiratory causes of death 
from the general patient profile of the disease (ie, exposure 
to tobacco smoke, advanced age).
Patients with symptomatic COPD receive therapeutic 
interventions which should include avoidance of toxic 
exposures (mainly from cigarette smoking), preventive 
vaccinations and pharmacotherapy.7 Pharmacotherapy 
has been shown to provide meaningful physiologic and 
symptomatic benefit as well as improving important longer 
term clinical aspects of the disease, such as exercise tolerance, 
health-related quality of life and exacerbation reduction.7 
Patients with COPD often receive multiple medications for 
their airway disease and for common comorbidities. The mul-
tiple potential interactions of COPD, comorbidities, and medi-
cations may result in unanticipated adverse events. Due to the 
higher risk in COPD for premature mortality and the preva-
lence of comorbidities, especially cardiovascular disease, it 
becomes prudent to continue to ascertain information regard-
ing the safety of therapeutic interventions for COPD.
Inhaled anticholinergics have been considered as a first-
line option for the treatment of symptomatic COPD since the 
initial introduction of ipratropium bromide over two decades 
ago.7,8 Tiotropium is the only once-daily inhaled anticholin-
ergic and the only once-daily inhaled medication approved 
for use in COPD. Two drug product formulations have been 
investigated in clinical trials, a dry powder formulation 
delivered through the HandiHaler® inhalation device, and an 
aqueous solution, delivered via the Respimat® inhaler, a novel, 
propellant-free delivery system. A previous report described 
adverse events from a pooled analysis of 19 clinical trials with 
tiotropium HandiHaler®,9 while a more recent report focused 
on cardiovascular safety from a database of HandiHaler® 
(26 trials) and Respimat® (four trials)10 (Table 1). Given that 
the HandiHaler® formulation is the only available form of 
tiotropium in the majority of countries where tiotropium 
can be prescribed (over 90 countries worldwide), the present 
report is a summary of data with tiotropium HandiHaler® in 
the treatment of COPD. The clinical trial data reviewed is from 
the subset of HandiHaler® studies described in the report by 
Celli and colleagues, which only focused on cardiovascular 
events.10 The purpose of this report is to review key safety data 
that will assist health care professionals in decisions regarding 
prescribing of tiotropium delivered via the HandiHaler®.
Methods
Study population
The methodology used is similar to that described in the 
report by Celli and colleagues and Kesten and colleagues, 
with the major difference being that rate differences rather 
than rate ratios are calculated.9,10
The pooled safety database consists of 26 phase III and 
IV HandiHaler® completed clinical trials as of March 2009 
in the tiotropium (Boehringer Ingelheim GmbH, Ingelheim, 
Germany) project database. For inclusion, all trials used a 
placebo-controlled, double-blind and parallel-group study 
design. Trials were restricted to studies of COPD of at 
least four weeks’ duration. Trials of less than four weeks’ 
duration were excluded as minimal adverse events are 
generally observed in such short-term trials, which may 
therefore not reflect an accurate incidence during chronic 
maintenance treatment. The Boehringer Ingelheim study 
numbers of the 26 trials of tiotropium were as follows: 
205.114/117,11 205.115/128,11 205.123,12 205.124,13 
205.130,14 205.131,15 205.137,14 205.214,16 205.215,17 
205.218,18 205.223,19 205.230,20 205.235,21 205.247,22 
Table 1 Clinical trials included in the pooled Tiotropium 
HandiHaler® analysis
BI Trial Number Duration 
(Weeks)
Placebo 
(# treated 
patients)
Tiotropium 
(# treated 
patients)
205.114–117 48 191 279
205.115–128 48 180 271
205.123 6 40 81
205.124 4 30 65
205.130 24 201 209
205.137 24 199 193
205.131 6 100 98
205.214 48 510 500
205.215 12 54 46
205.218 4 41 40
205.223 6 130 131
205.230 25 53 55
205.235 210 3006 2986
205.247 25 117 117
205.256 36 288 266
205.257 12 403 1236
205.259 48 305 608
205.266 24 915 914
206.269 16 127 123
205.270 52 73 69
205.276 12 195 200
205.281 12 117 107
205.282 12 164 147
205.284 12 96 100
205.294 8 86 80
205.301 12 244 228International Journal of COPD 2009:4 399
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205.256,23 205.257,24 205.259,25 205.266,26 205.269, 
205.270,27 205.276,28 205.281,29 205.282,30 205.284,31 
205.294,32 and 205.301.33
Trials used similar inclusion and exclusion criteria as 
previously described.9,10 In brief, inclusion criteria were: 
diagnosis of COPD, FEV1  70% of forced vital capacity 
(FVC), age  40 years,  10 pack-years of smoking. Exclu-
sion criteria are summarized as follows: diagnosis of asthma, 
symptomatic prostatic hypertrophy or bladder neck obstruc-
tion, narrow-angle glaucoma, and known hypersensitivity to 
study medication or components. Significant disease other 
than COPD which could significantly confound the study 
results or preclude study completion was also an exclusion 
criterion. Other exclusion criteria in earlier trial protocols 
were heart failure resulting in a hospitalization in the previous 
three years, cardiac arrhythmia requiring drug treatment, or 
myocardial infarction within the past year. Nevertheless, 
heart failure and ischemic heart disease were not necessar-
ily exclusion criteria. Changes in exclusion criteria in more 
recent trials such as UPLIFT were life-threatening cardiac 
arrhythmia or arrhythmia requiring a change in medication 
within the last year, heart failure resulting in hospitalization 
in the past year and myocardial infarction within the preced-
ing six months. Written informed consent was obtained from 
all patients and ethics committee approval was obtained for 
all protocols.
Use of theophyllines, inhaled corticosteroids, modest 
daily doses of oral corticosteroids (provided the dosing was 
stable) and short-acting β-agonists were permitted in all 
trials. The four-year UPLIFT® trial (5,992 patients), trial 
205.266 (1,829 patients), trials 205.259, 205.270, 205.282, 
and 205.284 also permitted use of long-acting β-agonists 
(LABAs) as prescribed.21,25,26,30,31
Study variables
Spirometry was performed in all studies according to 
accepted standards.34 A variety of efficacy endpoints were 
incorporated into individual protocols such as lung volumes, 
exercise testing, patient-reported outcome questionnaires and 
exacerbation of COPD. All study visits included collection of 
adverse events.
Adverse event reporting
Adverse events during the conduct of the trial were reported 
by the investigational sites to Boehringer Ingelheim. 
An adverse event was defined as any untoward medical 
occurrence occurring during the trial which did not 
necessarily have to have a causal relationship with the 
treatment. A serious adverse event was defined as any 
adverse event that resulted in death, was immediately life-
threatening, resulted in persistent or significant disability/
incapacity, required or prolonged patient hospitalization, 
or was deemed serious for any other reason representing a 
significant hazard, which is comparable to the aforemen-
tioned criteria. In trial 205.266, nonserious adverse events 
were a priori not to be recorded.26 Adverse events, serious 
adverse events, and fatal adverse events are described 
separately.
All adverse events included in the analysis are from the 
period during which the patient received study drug for 
30 days (defined as the period at risk) and as reported by 
the investigator. Vital status information was collected from 
patients who prematurely discontinued study medication only 
in the four-year UPLIFT trial and in trial 205.266 and is not 
included in the present analysis.10,26
Categorization of adverse events
The Medical Dictionary for Regulatory Activities 
(MedDRA) version 11.1 was used to code all adverse 
events. The dictionary includes quite specific terms, 
noted as preferred terms (PT). Each PT is categorized 
under organ classes, referred to as system organ classes 
(SOC) within MedDRA. Due to the needs of the tiotro-
pium project, several of the SOCs from MedDRA were 
modified during the development program and are used 
for the present report. The preferred terms provide a very 
granular level of detail; however, the disadvantage of 
the granularity is that similar adverse event reports can 
be divided among many terms, which may lead to small 
numbers of events at a PT level. In order to improve the 
precision of the rate estimates for adverse events, similar 
PTs have been combined to capture clinical endpoints of 
interest. For example, the endpoint of stroke represents a 
composite of multiple PTs as there is no single PT noted 
as “stroke”. There are 66 preferred terms including within 
stroke (eg, cerebrovascular accident, brain stem infarc-
tion, cerebral artery occlusion, cerebral artery embolism, 
cerebral artery thrombosis, hemorrhagic stroke). Tables 
include PTs or combined PTs under their specific organ 
system. An individual patient may be represented in several 
preferred terms or combined preferred terms but will only 
be represented once when the data is displayed according 
to the SOC (total). A similar approach has been used and 
is described in previous publications.9,10
A composite endpoint of major adverse cardiovascular 
events was included in the analysis. The composite International Journal of COPD 2009:4 400
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endpoint consists of fatal events in the SOC cardiac 
disorders and SOC vascular disorders along with myo-
cardial infarction (fatal and nonfatal), stroke (fatal and 
nonfatal) and sudden death, sudden cardiac death and 
cardiac death. Nonfatal myocardial infarction and non-
fatal stroke were removed for the composite endpoint of 
fatal cardiovascular events.
Statistical methods
The following definitions were used:
Total exposure time to study drug = total days from 1st 
dose to last dose of study drug.
Time at risk = from 1st administration of drug to 30 days 
following the last dose of study drug or until the onset of the 
specific adverse event analyzed, whichever came first.
Incidence rate (IR) = number of patients with an event/
cumulative time at risk within a treatment group.
Incidence rate difference (RD) = IR (tiotropium) – IR 
(placebo).
Incidence rate differences were estimated based on 
the method described by Greenland and Robins.35 The 
95% confidence interval (CI) was calculated for each rate 
difference in order to describe the precision of the effect 
estimate.35 A RD  0 indicates a decreased risk with 
tiotropium and a RD  0 indicates a decreased risk with 
placebo. A P value less than 0.05 is indicated when the 
width of the CI excludes the value 0. Potential heterogeneity 
among trials for adverse events, serious adverse events, and 
fatal adverse events was explored prior to combining trials 
using Zelen’s test.37
Results
Study population
The number of patients (patient-years of exposure) was 7,865 
(10,578) for placebo and 9,149 (11,958) for tiotropium. 
Baseline demographics (Table 2) were balanced between 
treatment groups. A total of 4,508 (26.5%) patients 
prematurely discontinued study medication with a higher 
discontinuation rate in the placebo than the tiotropium treated 
patients (30.9% vs. 22.7%, respectively). Zelen’s test for 
adverse events (P = 0.42), serious adverse events (P = 1.00) 
and fatal adverse events (P = 1.00) did not indicate hetero-
geneity among the 26 HandiHaler® trials.
Baseline (ie, taken at study entry) concomitant respiratory 
medication use was balanced between treatment groups. 
More than 50% of patients were receiving inhaled 
corticosteroids, 39% were receiving LABAs, and 22% were 
receiving theophyllines (Table 3).
Overall adverse events
A majority of patients (62%) experienced at least one adverse 
event during the trial, with a lower risk of experiencing 
an event in the tiotropium group as observed by the 
incidence RD (tiotropium minus placebo) of -18 patients 
per 100 patient-years at risk (Table 4). Reductions 
in risk were documented for serious adverse events 
(difference = -1.4 patients per 100 patient-years) and for 
fatal events (difference = -0.6 patients per 100 patient-years). 
All values excluded an upper limit of 0 in the CI.
Cardiovascular and lower respiratory 
adverse events
The results presented in this section include a list of pooled 
terms representing the cardiovascular and lower respiratory 
Table 2 Baseline characteristics of patients in the placebo and 
tiotropium groups
Characteristic Placebo (n 
= 7,865)
Tiotropium 
(n = 9,149)
Age (years)* 64.7 (8.9) 64.5 (8.8)
Male (%) 76.0 76.0
Current smoker (%) 33.0 33.8
Baseline spirometry
  Fev1 (L)* 1.15 (0.46) 1.17 (0.47)
  Fev1 (% predicted)* 40.8 (14.1) 41.3 (14.3)
  FvC (L)* 2.50 (0.82) 2.47 (0.81)
  Fev1/FvC* 0.47 (0.12) 0.48 (0.13)
Note: *Mean (standard deviation).
Abbreviations: Fev1, forced expiratory volume in one second; FvC, forced vital 
capacity.
Table 3 Baseline concomitant respiratory medications in the 
placebo and tiotropium groups
Placebo  
(n = 7,865) 
n (%)
Tiotropium 
(n = 9,149) 
n (%)
Any respiratory medication 6,637 (84.4) 7,499 (82.0)
Short-acting inhaled anticholinergicsa 3,219 (40.9) 3,627 (39.6)
Long-acting inhaled anticholinergics 91 (1.2) 94 (1.0)
Short-acting inhaled β2-agonistsa 2,823 (35.9) 3,396 (37.1)
Long-acting inhaled β2-agonistsb 3,184 (40.5) 3,369 (36.8)
Inhaled corticosteroidsb 4,407 (56.0) 5,024 (54.9)
Oral steroids 289 (3.7) 374 (4.1)
Theophylline compounds 1,685 (21.4) 2,076 (22.7)
Mucolytics 401 (5.1) 458 (5.0)
Leukotriene receptor antagonists 176 (2.2) 189 (2.1)
Supplemental oxygen 399 (5.1) 414 (4.5)
Notes: Baseline period for medications is defined as time before consent date 
and ending after or equal to consent date. aalone or in combination; balone or in 
combination.International Journal of COPD 2009:4 401
Tiotropium HandiHaler®: a safety review Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
terms and categories of particular interest. The selection was 
based on clinical categories that are of public health interest or 
on possible pathophysiologic associations suggested by either 
previous published reports or potential biologic mechanisms. 
Individual patients may be represented in multiple categories, 
but a patient is only represented once within a category or at 
the SOC level (ie, cardiac disorder SOC total). For example, 
all patients reported to have a myocardial infarction would be 
counted with the pooled term “ischemic heart disease.”
Overall, there were 1,511 patients with at least one 
cardiac adverse event and 1,233 patients with at least one 
vascular adverse event (Table 5). The RD (95% CI) for 
any cardiac event (tiotropium minus placebo) was -0.79 
(-1.48, -0.09) and for any vascular event was -0.14 
(-0.77, 0.49). Tiotropium was associated with a decreased risk 
for a cardiac adverse event and no increased risk for a vascular 
adverse event. The absence of increased risk was observed for 
the most common events in the categories of hypertension, 
ischemic heart disease and cardiac failure. Cardiac failure 
occurred at a decreased rate with tiotropium relative to 
placebo (RD (95% CI) = -0.47 (-0.84, -0.10). For myocardial 
infarction and stroke, the RDs (95% CI) were -0.18 (-0.42, 
0.05) and 0.04 (-0.20, 0.27), respectively. The incidence 
rates for stroke were similar between the two treatment arms. 
There was no indication of an increased risk for myocardial 
infarction or stroke associated with tiotropium.
Table 5 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for adverse events according to selected organ 
systems and adverse event endpoints
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–Placebo
n IR N IR RD (95% CI)
Cardiac disorders 750 7.26 761 6.47 -0.79 (-1.48, -0.09)*
Atrial fibrillation/flutter 141 1.27 143 1.14 -0.12 (-0.40, 0.17)
Cardiac arrest 31 0.28 22 0.17 -0.09 (-0.22, 0.03)
Cardiac failure 254 2.32 229 1.83 -0.47 (-0.84, -0.10)*
Ischemic heart disease 279 2.56 282 2.29 -0.28 (-0.69, 0.12)
Myocardial infarction 105 0.94 95 0.75 -0.18 (-0.42, 0.05)
Palpitations 54 0.48 67 0.53 0.04 (-0.14, 0.22)
Supraventricular tachycardia 25 0.22 32 0.25 0.03 (-0.09, 0.16)
Tachycardia (nonventricular) 49 0.44 60 0.48 0.02 (-0.15, 0.19)
Ventricular tachycardia/fibrillation 27 0.24 19 0.15 -0.09 (-0.20, 0.03)
Vascular disorders 588 5.68 645 5.50 -0.14 (-0.77, 0.49)
Aneurysm 40 0.36 51 0.40 0.05 (-0.10, 0.21)
Hypertension 368 3.47 379 3.13 -0.34 (-0.82, 0.13)
Stroke 94 0.85 109 0.87 0.04 (-0.20, 0.27)
Lower respiratory disorders 3648 65.02 3716 53.16 -14.2 (-17.0, -11.5)*
COPD exacerbation 2829 43.18 2793 34.87 -8.90 (-11.0, -6.83)*
Pneumonia 525 4.96 572 4.78 -0.25 (-0.83, 0.33)
respiratory failure 209 1.89 183 1.46 -0.38 (-0.71, -0.05)*
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time 
at risk); rD (95% CI), rate difference (95% CI) per 100 patient-years of time at risk; terms used are composed of multiple MedDrA-preferred terms; *P  0.05.
Table 4 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for adverse events, serious adverse events 
and fatal adverse events
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–placebo
n IR n IR RD (95% CI)
Adverse events 5071 145.3 5560 133.1 -17.5 (-22.9, -12.2)*
Serious adverse events 2088 24.1 2237 22.6 -1.41 (-2.81, -0.00)*
Fatal adverse events 472 4.27 445 3.55 -0.63 (-1.14, -0.12)*
Abbreviations: CI, confidence interval; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time at risk); RD, rate difference (95% CI) per 
100 patient-years of time at risk, *P  0.05.International Journal of COPD 2009:4 402
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Lower respiratory tract events were common and occurred 
with a lower rate in the tiotropium group (RDs, -14.2; 95% 
CI: -17.0, -11.5). The most common event was reported as 
a COPD exacerbation, which along with respiratory failure, 
occurred with a tiotropium minus placebo rate difference and 
upper limit of the CI below zero.
There were 899 patients with at least one serious cardiac 
event and 274 with at least one serious vascular event (Table 6). 
The RD (95% CI) for any serious cardiac event (tiotropium–
placebo) was -0.79 (-1.30, -0.27) and 0.14 (-0.13, 0.42) for 
any serious vascular event. Tiotropium was not associated with 
a significantly increased risk for either a cardiac or vascular 
serious adverse event, including the most common events in 
the categories of ischemic heart disease and cardiac failure. 
The incidence rate for serious events reported as ischemic heart 
disease was lower with tiotropium and there was a trend for a 
reduced rate for cardiac failure. For serious myocardial infarc-
tion and stroke, the RDs (95% CI) were -0.18 (-0.41, 0.05) 
and 0.07 (-0.14, 0.29), respectively.
Lower respiratory tract serious adverse events were 
common and occurred with a lower rate in the tiotropium 
group (RDs -2.23; 95% CI: -3.20, -1.27). The most common 
event was reported as a COPD exacerbation, which, along 
with respiratory failure, occurred with a rate difference and 
upper limit of the CI below zero in the tiotropium group.
Major adverse cardiovascular event
The incidence rates and rate differences for the composite 
endpoint of a major adverse cardiovascular event are displayed 
in Table 7. There was a lower incidence rate for a major 
cardiovascular event in the tiotropium group relative to the 
placebo group (-0.45 patients per 100 patient-years at risk) 
and a lower rate for fatal cardiovascular events (-0.32 patients 
per 100 patient-years at risk). A further analysis was performed 
that includes the nonspecific preferred term “death” (used 
when a cause of death could not be determined) assuming 
that the cause of death in all cases was cardiovascular. 
For this expanded endpoint, the rate difference remained 
less than 0 (RD = -0.28; 95% CI: -0.58, 0.02).
Anticholinergic events
Anticholinergic  medications  are  known  to  exert 
pharmacologic effects on multiple organ systems. Inhaled 
quaternary anticholinergics do not cross the blood brain 
barrier to any relevant extent and appear to be devoid of 
central nervous system effects. Tables 8 and 9 document 
Table 6 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for serious adverse events cases according to 
selected organ systems and adverse event endpoints
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–placebo
N IR n IR RD (95% CI)
Cardiac disorders 466 4.33 433 3.53 -0.79 (-1.30, -0.27)*
Ischemic heart disease* 196 1.78 181 1.45 -0.34 (-0.67, -0.01)*
Atrial fibrillation/flutter 84 0.75 81 0.64 -0.10 (-0.32, 0.11)
Cardiac arrest 30 0.27 22 0.17 -0.09 (-0.21, 0.03)
Cardiac failure 165 1.49 154 1.22 -0.26 (-0.56, 0.04)
Myocardial infarction 102 0.92 92 0.73 -0.18 (-0.41, 0.05)
Palpitations 5 0.04 6 0.05 0.00 (-0.05, 0.05)
Supraventricular tachycardia 13 0.12 15 0.12 0.01 (-0.08, 0.09)
Tachycardia (nonventricular) 6 0.05 7 0.06 -0.01 (-0.06, 0.05)
Ventricular tachycardia/fibrillation 21 0.19 17 0.13 -0.05 (-0.15, 0.05)
Vascular disorders 122 1.10 152 1.21 0.14 (-0.13, 0.42)
Aneurysm 27 0.24 31 0.24 0.01 (-0.12, 0.14)
Hypertension 21 0.19 16 0.13 -0.06 (-0.16, 0.04)
Stroke 74 0.66 91 0.72 0.07 (-0.14, 0.29)
Lower respiratory disorders 1301 13.4 1265 11.3 -2.23 (-3.20, -1.27)*
COPD exacerbation 951 9.44 921 7.95 -1.58 (-2.37, -0.78)*
Pneumonia 370 3.41 390 3.18 -0.26 (-0.73, 0.22)
respiratory failure 189 1.71 158 1.25 -0.40 (-0.72, -0.09)*
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time 
at risk); rD (95% CI), rate difference (95% CI) per 100 patient-years of time at risk; terms used are composed of multiple MedDrA-preferred terms; *P  0.05.International Journal of COPD 2009:4 403
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the adverse event and serious adverse event reported 
incidence rates and rate differences for presumed, potential 
or hypothetical events that may be a consequence of 
anticholinergic pharmacology. Cardiovascular and lower 
respiratory events are noted in the preceding tables and 
are not repeated in Tables 8 and 9. As with the previous 
analysis, similar preferred terms have been combined to 
increase the absolute numbers and improve the precision 
of the estimated rates and RDs.
Typical expected inhaled anticholinergic effects such 
as dry mouth, constipation, and urinary difficulties were 
observed in the safety database. Dry mouth was the most 
common event and showed the largest rate difference 
(RD = 1.65; 95% CI: 1.28, 2.03). Additionally, under 
gastrointestinal disorders, higher incidence rates were 
observed for dyspepsia, gastroesophageal reflux, and gastro-
intestinal obstruction. For renal and urinary disorders, higher 
incidence rates with tiotropium were observed for dysuria and 
urinary retention. A higher risk of pharyngitis was reported 
with tiotropium, which may reflect reporting related to drying 
of the upper airways. There were no overall imbalances with 
regard to nervous system disorders, psychiatric disorders, 
and metabolism disorders.
Fatal events
As noted, there was a lower incidence rate for a fatal event 
during treatment in the tiotropium HandiHaler® group relative 
to the placebo group, with the upper limit of the CI being 
less than zero. A Forest plot of the rate differences for the 
individual trials is displayed in Figure 1. The overall analysis 
is dominated by the UPLIFT trial. Most of the individual trials 
are associated with wide CIs, a few of which have incidence 
rates that are higher in the tiotropium group.
Causes of death are presented according to system organ 
class where the frequency is at least 3% of the total number of 
deaths in either treatment period (Table 10). As expected, the 
most common causes of death occurred in the system organ 
classes of lower respiratory and cardiac. In all cases there was 
no imbalance indicating an excess risk with tiotropium.
Causes of death according to preferred terms based on 
a frequency of at least 10 events in a treatment group are 
displayed in Table 11. The most common causes of death 
were reported as COPD exacerbation, respiratory failure and 
pneumonia. The events where the upper limit of the CI was 
less than zero were respiratory failure and sepsis.
Discussion
Tiotropium HandiHaler® was introduced in Europe in 2002 
and over the subsequent years has become available in over 
90 countries. Tiotropium HandiHaler® has been demonstrated 
to be effective in the treatment of COPD with numerous 
published randomized, double-blind, controlled clinical 
trials showing improvements in airflow, air trapping, hyper-
inflation, symptoms such as breathlessness (as measured 
by questionnaires and requirement for rescue short-acting 
β-agonists), exercise duration during cycle and treadmill 
exercise testing, health-related quality of life (as measured 
by the St. George’s Respiratory Questionnaire) and exacerba-
tions.11,14–21,23–27 The safety profile of tiotropium is generally 
related to anticholinergic mechanisms although other events 
are noted in package inserts based on imbalances in clinical 
trials where a potential mechanism is uncertain.
Additional data regarding safety may be uncovered 
through evaluation of peer-reviewed scientific publications. 
Such safety data tend to be based on relatively small numbers 
of patients participating in a single clinical trial or based on 
isolated case reports or case series. Data has previously been 
published on a pooled analysis of 19 clinical trials;9 however, 
the largest clinical trial of tiotropium, UPLIFT, had not yet 
been completed.21 A recent publication regarding safety 
focused on cardiovascular adverse events from a 30-trial data-
base including two formulations of tiotropium.10 The present 
document more than doubles the sample size in the 19 trial 
publication (total of 7,819 patients) but is restricted to the 26 
HandiHaler® formulation trials in the publication by Celli and 
colleagues, as the other formulation is not as widely avail-
able as the HandiHaler® formulation.10 Furthermore, while 
cardiovascular safety data has been presented by Celli and 
Table 7 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for a major adverse cardiovascular event
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–placebo
n IR n IR RD (95% CI)
Major adverse Cv event 297 2.71 277 2.22 -0.45 (-0.85, -0.05)*
Fatal Cv event 145 1.30 121 0.96 -0.32 (-0.59, -0.05)*
Abbreviations: CI, confidence interval; CV, cardiovascular; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time at risk); RD (95% CI), rate 
difference (95% CI) per 100 patient-years of time at risk; terms used are composed of multiple MedDrA-preferred terms; *P  0.05.International Journal of COPD 2009:4 404
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colleagues, additional data regarding lower respiratory, and 
anticholinergic events as well as fatal events associated with 
tiotropium 18 µg daily delivered via the HandiHaler® device 
has been included in the present report. The clinical trial 
database of the 26 tiotropium HandiHaler® trials includes 
7,865 placebo treated patients and 9,149 tiotropium treated 
patients, which corresponds to 10,578 and 11,958 patient-
years of exposure respectively.
The 26 trial analyses show incidence rates that are lower 
in the tiotropium group relative to the placebo group for 
Table 8 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for potential anticholinergic adverse events
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–Placebo
N IR N IR RD (95% CI)
Eye disorders 322 3.01 366 3.02 0.00 (-0.45, 0.46)
Glaucoma 29 0.26 33 0.26 0.01 (-0.12, 0.14)
vision blurred 51 0.46 52 0.41 -0.06 (-0.23, 0.11)
Gastrointestinal disorders 1151 12.0 1553 14.9 2.44 (1.42, 3.46)*
Abdominal pain 151 1.37 187 1.50 0.07 (-0.24, 0.38)
Constipation 135 1.22 196 1.57 0.34 (0.04, 0.64)*
Dry mouth 142 1.29 373 3.06 1.65 (1.28, 2.03)*
Dyspepsia (including reflux) 288 2.66 386 3.19 0.42 (-0.02, 0.86)
Dysphagia 19 0.17 22 0.17 -0.00 (-0.10, 0.10)
GI obstruction 25 0.22 46 0.36 0.15 (0.01, 0.28)*
Gastroesophageal reflux 203 1.86 286 2.33 0.37 (-0.00, 0.74)
Stomatitis 27 0.24 45 0.36 0.09 (-0.05, 0.23)
Respiratory (upper) disorders 1648 19.1 1985 20.6 0.75 (-0.55, 2.05)
Laryngitis 29 0.26 45 0.36 0.08 (-0.05, 0.22)
Pharyngitis 603 5.92 771 6.74 0.73 (0.06, 1.40)*
Metabolism and nutrition disorders 531 5.08 547 4.61 -0.49 (-1.07, 0.10)
Blood glucose increased 175 1.60 173 1.39 -0.22 (-0.54, 0.09)
Body temperature increased 106 0.96 135 1.08 0.05 (-0.21, 0.31)
Dehydration 23 0.21 38 0.30 0.10 (-0.03, 0.23)
Nervous system disorders 774 7.58 907 7.92 -0.11 (-0.86, 0.64)
Dizziness 210 1.92 237 1.92 -0.10 (-0.46, 0.26)
Headache 282 2.60 346 2.83 -0.05 (-0.48, 0.39)
Sleep disturbance 150 1.36 193 1.56 0.16 (-0.15, 0.47)
Syncope 43 0.39 53 0.42 0.04 (-0.13, 0.20)
Psychiatric disorders 415 3.89 497 4.14 0.12 (-0.40, 0.65)
Anxiety symptoms/fears 152 1.38 168 1.35 -0.12 (-0.42, 0.18)
Cognitive impairment 50 0.45 61 0.48 0.02 (-0.15, 0.20)
Confusion 18 0.16 13 0.10 -0.07 (-0.16, 0.03)
Depression 140 1.26 175 1.40 0.14 (-0.16, 0.44)
Insomnia 121 1.10 171 1.38 0.26 (-0.02, 0.55)
restless/agitation 12 0.11 12 0.09 -0.03 (-0.12, 0.05)
Renal and urinary disorders 258 2.37 294 2.38 -0.00 (-0.40, 0.39)
Dysuria 13 0.12 35 0.28 0.16 (0.05, 0.27)*
renal failure 56 0.50 60 0.47 -0.02 (-0.20, 0.16)
Urinary retention 27 0.24 48 0.38 0.14 (-0.00, 0.28)
Urinary tract infection 222 2.04 281 2.28 0.21 (-0.17, 0.58)
Abbreviations: CI, confidence interval; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time at risk); RD (95% CI), rate difference (95% CI) 
per 100 patient-years of time at risk; terms used are composed of multiple MedDrA-preferred terms; *P  0.05.International Journal of COPD 2009:4 405
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overall adverse events, serious adverse events and all-cause 
mortality. There is no evidence to support an increase in 
adverse events, including fatal adverse events, under the 
system organ classes of cardiac or vascular disorders. Lower 
incidence rates with tiotropium relative to placebo were 
observed for a composite endpoint of major cardiovascular 
events. Additionally, lower rates were observed for lower 
respiratory tract events including exacerbations of COPD and 
Table 9 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for potential anticholinergic serious adverse 
events
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–placebo
N IR N IR RD (95% CI)
Eye disorders 31 0.28 34 0.27 0.01 (-0.13, 0.14)
Glaucoma 1 0.01 2 0.02 0.01(-0.02, 0.01
vision blurred 1 0.01 1 0.01 -0.00 (-0.02, 0.02)
Gastrointestinal disorders 219 2.00 237 1.91 -0.07 (-0.43, 0.29)
Abdominal pain 26 0.23 23 0.18 -0.05 (0.17, 0.06)
Constipation 5 0.04 5 0.04 -0.00 (0.06, 0.05)
Dry mouth 0 0 0 0 0
Dyspepsia (including reflux) 19 0.17 21 0.17 0.00 (-0.10, 0.11)
Dysphagia 4 0.04 4 0.03 -0.00 (-0.05, 0.04)
GI obstruction 21 0.19 39 0.31 0.12 (-0.00, 0.25)
Gastroesophageal reflux 10 0.09 12 0.09 0.01 (-0.07, 0.08)
Stomatitis 0 0.00 2 0.02 0.02 (-0.01, 0.04)
Respiratory (upper) disorders 42 0.38 50 0.40 0.02 (-0.14, 0.18)
Laryngitis 1 0.01 1 0.01 -0.00 (-0.02, 0.02)
Pharyngitis 4 0.04 1 0.01 -0.03 (-0.07, 0.01)
Metabolism and nutrition disorders 65 0.58 65 0.51 -0.07 (-0.26, 0.12)
Blood glucose increased 15 0.13 26 0.20 0.06 (-0.04, 0.17)
Body temperature increased 8 0.07 13 0.10 0.03 (-0.04, 0.11)
Dehydration 12 0.11 20 0.16 0.05 (-0.04, 0.14)
Nervous system disorders 171 1.55 186 1.49 -0.03 (-0.35, 0.28)
Dizziness 22 0.20 19 0.15 -0.04 (-0.15, 0.07)
Headache 4 0.04 5 0.04 0.01 (-0.04, 0.06)
Sleep disturbance 4 0.04 0 0.00 -0.04 (-0.07,  -0.00)
Syncope 12 0.11 24 0.19 0.08 (-0.01, 0.18)
Psychiatric disorders 48 0.43 36 0.28 -0.14 (-0.30, 0.10)
Anxiety symptoms/fears 8 0.07 4 0.03 -0.04 (-0.10, 0.02)
Cognitive impairment 9 0.08 5 0.04 -0.04 (-0.11, 0.02)
Confusion 3 0.03 2 0.02 -0.01 (-0.05, 0.03)
Depression 18 0.16 14 0.11 -0.05 (-0.14, 0.05)
Insomnia 1 0.01 0 0.00 -0.01 (-0.03, 0.01)
restless/agitation 2 0.02 0 0.00 -0.02 (-0.05, 0.01)
Renal and urinary disorders 70 0.63 87 0.69 0.07 (-0.14, 0.28)
Dysuria 0 0.00 1 0.01 0.01 (-0.01, 0.02)
renal failure 26 0.23 38 0.30 0.07 (-0.06, 0.20)
Urinary retention 11 0.10 19 0.15 0.06 (-0.03, 0.15)
Urinary tract infection 22 0.20 31 0.24 0.05 (-0.07, 0.17)
Abbreviations: CI, confidence interval; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time at risk); RD (95% CI), rate difference (95% CI) 
per 100 patient-years of time at risk; terms used are composed of multiple MedDrA-preferred terms; *P  0.05.International Journal of COPD 2009:4 406
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events reported as respiratory failure. For the above endpoints 
the upper limit of the CIs were below zero.
The analysis also confirms the association of tiotropium 
with several recognized anticholinergic effects such as dry 
mouth, constipation, dyspepsia and gastroesophageal reflux, 
and urinary difficulties. The increased size of the database 
results in more precise estimates of the incidence rate with 
tiotropium relative to the control group. The publication of 
the database results should provide additional information 
that improves the assessment of risks and benefits when 
prescribing tiotropium HandiHaler® to patients with COPD.
Previous published analyses have relied on incidence 
rate ratios or hazard ratios which reflect the relative risk of 
tiotropium to the comparator study group. The current report 
Treatment
# events
Treatment
Yrs at risk
Control
# events
Control
Yrs at risk
Favors treatment
Source Weight Rate difference (95% Cl)
205.114 3 244 5 155 1.6 –1.99 (5.14, 1.15)
205.115 4 232 2 141 1.5 0.31 (–2.29, 2.90)
205.123 0 16 0 8 0.1
205.124 0 10 1 4 0.1 –23.37 (69.17, 22.43)
205.130 0 107 4 91 0.8 –4.40 (–8.72, –0.09)  
205.131 0 19 19 1
1
0.2 –5.17 (15.31, 4.96)
205.137 1 95 95 0.8 0.00 (–2.91,2.91)
205.214 7 451 8 441 3.8 –0.26 (–1.97, 1.44)
205.215 0 14 0 16 0.1
205.218 1 6 0 6 0.1 16.07 (–15.43, 47.56)
205.223 0 26 0 25 0.2
205.230 1 25 0 24 0.2 3.96 (–3.80, 11.71)
205.235 381 9281 411 8575 76.6 –0.69 (–1.31, –0.07)
205.247 0 57 0 58 0.5
205.256 3 202 6 199 1.7 –1.53 (–4.47, 1.41)
205.257 5 356 2 113 1.5 –0.37 (–3.12, 2.38)
205.259 13 527 2 249 2.9 1.66 (–0.08, 3.41)
205.266 22 489 19 453 4.0 0.31 (–2.36, 2.97)
205.269 0 39 0 40 0.3
205.270 1 60 2 67 0.5 –1.33 (–6.59, 3.93)
205.276 1 59 4 56 0.5 –5.48 (–13.26, 2.30)
205.281 0 33 1 37 0.3 –2.71 (–8.02, 2.60)
205.282 2 45 0 51 0.4 4.42 (–1.71,10.55)
205.284 0 30 0 28 0.2
205.294 0 19 1 20 0.2 –4.96 (–14.68, 4.76)
205.301 0 73 2 77 0.6 –2.61 (–6.23, 1.01)
Total 445 12519 472 11048 100.0 –0.63 (–1.14, –0.12)
–4  –3.5  –3  –2.5  –2  –1.5  –1  –0.5 0.5 1.5 1 0 2 4
Rate difference (95% Cl)
2.5 3 3.5
Favors control
Figure 1 Incidence rates, rate differences (tiotropium–placebo), and 95% confidence intervals (CI) for all-cause mortality in 26 Tiotropium HandiHaler® trials (total and within 
each trial).
Table 10 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for fatal cases according to organ system 
with a frequency of at least 3% of the total number of fatal cases
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–Placebo
n IR n IR RD (95% CI)
respiratory disorders (lower)** 165 1.48 147 1.16 -0.30 (-0.59, -0.00)*
Cardiac disorders 105 0.94 88 0.69 -0.24 (-0.47, -0.01)*
respiratory disorders (other)** 77 0.69 86 0.68 0.01 (-0.20, 0.23)
General disorders and administration site conditions 55 0.49 59 0.46 -0.01 (-0.19, 0.17)
Neoplasms benign, malignant and unspecified*** 52 0.46 47 0.37 -0.08 (-0.24, 0.09)
Infections and infestations*** 32 0.29 21 0.17 -0.11 (-0.23, 0.01)
Nervous system disorders 16 0.14 18 0.14 0.00 (-0.09, 0.10)
Notes: *P  0.05; **All primary system organ classes are defined by MedDRA with the exception of respiratory, thoracic, and mediastinal disorders which has been divided 
into three separate classes of respiratory system disorders: lower, upper, and other. ***Preferred terms with a secondary relationship to MedDrA SOC respiratory, thoracic 
and mediastinal disorders are not included.
Abbreviations: CI, confidence interval; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time at risk); RD (95% CI), rate difference (95% CI) 
per 100 patient-years of time at risk.International Journal of COPD 2009:4 407
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discusses the results in terms of incident rate differences. 
Expressions of the relative risk assist in understanding the 
increased or decreased risk of a compound which can readily 
be understood and compared to other compounds (recognizing 
the distinct limitations of cross-study and even indication 
comparisons). There are several limitations with this approach. 
When the denominator is zero, the risk is infinite and cannot 
be numerically expressed. The public health impact of the 
increased or decreased risk cannot be easily discerned and 
small numbers of events can lead to exaggerated conclusions. 
For example, an event rate of one per million exposed to Drug 
A compared to two per million exposed to Drug B, leads to a 
conclusion of twice the risk with Drug B; however, without 
knowing the incidence rate per unit time, the public health 
consequences are uncertain. On the other hand, expression 
of an incidence rate difference of one per 1,000 patient-
years exposed (or at risk) can lead to a more meaningful 
understanding. Nevertheless, in both situations, the availability 
of CIs is important to determine the reliability of the results.
While the majority of prospective, randomized, double-
blind clinical trials with inhaled anticholinergics have been 
conducted by Boehringer Ingelheim, several other studies 
warrant a brief discussion. The five-year Lung Health Study 
suggested an association of cardiovascular mortality with 
ipratropium although this seemed to be mainly in those 
patients not compliant with ipratropium.38,39 A two-year study 
found more deaths in the tiotropium-treated group compared 
to a group treated with salmeterol and fluticasone although 
equivalent effects were noted on exacerbations and more 
pneumonia was reported with combination therapy. Potential 
confounding and biases limits the interpretation beyond the 
primary exacerbation endpoint.40,41 
Meta-analysis have yielded conflicting results for a 
variety of reasons but mainly related to early studies having 
incomplete data and inability to adjust for exposure due to 
differential discontinuation with higher discontinuation rates 
in the placebo groups.42,43 The limitations have been described 
in a previous publication of tiotropium data.10 
Observational studies regarding mortality and inhaled 
anticholinergics have been reported; however, in general 
suffer from inability to adequately adjust for confounding by 
severity and diagnosis.44,45 As well, conflicting results have 
been reported, with increases, decreases and similar rates of 
events compared to control groups, which reflects differing 
methodologies but similar limitations.44–47 These issues limit 
such analyses to hypothesis generation and can be considered 
as being inferior to prospective controlled, double-blind 
studies where all patient level data is available.
Although the current study includes all patient level data 
and controls for differences in exposure between treatment 
groups, it is acknowledged that meta-analysis can have limita-
tions given that data from different trials are being combined. 
As the trials were conducted using generally consistent 
inclusion and exclusion criteria, the same diagnostic criteria 
and nearly identical approaches to data collection, potential 
problems in combining studies have been minimized.10,48,55 
In summary, the present report presents a robust and 
extensive analysis of over 17,000 patients participating in 
Table 11 Incidence rates and rate differences (tiotropium–placebo) per 100 patient-years for fatal cases by term with a frequency of at 
least 10 fatal cases
Placebo (n = 7,865) Tiotropium (n = 9,149) Tiotropium–placebo
N IR n IR RD (95% CI)
COPD exacerbation 68 0.61 65 0.51 -0.09 (-0.28, 0.10)
respiratory failure 51 0.46 33 0.26 -0.19 (-0.34, -0.03)*
Pneumonia 36 0.32 33 0.26 -0.05 (-0.19, 0.09)
Death 28 0.25 36 0.28 0.04 (-0.09, 0.17)
Myocardial infarction 24 0.21 20 0.16 -0.05 (-0.16, 0.06)
Lung neoplasm malignant 19 0.17 21 0.17 0.00 (-0.11, 0.11)
Cardiac arrest 17 0.15 9 0.07 -0.08 (-0.16, 0.01)
Sepsis 17 0.15 8 0.06 -0.08 (-0.17, -0.00)*
Cardiac failure 10 0.09 14 0.11 0.02 (-0.06, 0.10)
Sudden death 11 0.10 12 0.09 -0.00 (-0.08, 0.08)
Cardiac failure congestive 10 0.09 6 0.05 -0.04 (-0.11, 0.02)
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; n, number of patients with an event; IR, incidence rate (per 100 patient-years of time 
at risk); rD (95% CI), rate difference (95% CI) per 100 patient-years of time at risk; terms may consist of several preferred terms; *P  0.05.International Journal of COPD 2009:4 408
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tiotropium HandiHaler® clinical trials and incorporation 
of all patient level data during treatment in a defined set of 
26 randomized double-blind, placebo-controlled trials. The 
results indicate that tiotropium HandiHaler® does not increase 
the overall risk for fatal events and cardiovascular events. 
On the contrary, there appears to be a relatively consistent 
pattern or incidence rate ratios below 0 for mortality, 
cardiovascular events, and lower respiratory tract events 
with tiotropium HandiHaler® 18 µg daily. Anticholinergic 
events are observed with tiotropium and the incidence rate 
differences reported may assist health care providers in their 
prescribing decisions. Based on the overall assessment of 
efficacy and safety, tiotropium HandiHaler® is considered to 
continue to exhibit a highly favorable benefit to risk profile 
in the treatment of COPD.
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